MannKind (MNKD) vs Nanobiotix S.A. (NBTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nanobiotix S.A. (NBTX) has outperformed MannKind (MNKD) over the past year, gaining 17.4% versus a loss of 38.9%. Over five years, NBTX leads with a +92.0% price change compared with -32.2% for MNKD. Nanobiotix S.A. is the larger company by market cap ($1.17 billion vs $1.10 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNKD | NBTX |
|---|---|---|
| Share price | $3.42 | $22.90 |
| Market cap | $1.10B | $1.17B |
| 1-day change | -0.87% | -6.99% |
| YTD return | -39.15% | +6.49% |
| 1-year return | -38.94% | +17.41% |
| 5-year return | -32.22% | +92.04% |
| Forward P/E | 26.82 | — |
| EPS (TTM) | $-0.14 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.51 | $57.14 |
| 52-week low | $2.23 | $14.78 |
| Distance from 52-week high | -47.47% | -59.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +129.24% | +135.28% |
| Average volume | 4.48M | 148.97K |
| Shares outstanding | 321.54M | 50.92M |
| Employees | 591 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NBTX has outperformed MNKD by 56.3 percentage points over the past year.
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees
About Nanobiotix S.A.
NBTX stock →Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
MNKD vs NBTX FAQ
Which is bigger, MannKind or Nanobiotix S.A.?
Nanobiotix S.A. (NBTX) is larger, with a market capitalization of $1.17B compared with $1.10B for MannKind (MNKD).
Which stock has performed better over the past year, MNKD or NBTX?
NBTX returned +17.41% over the past 12 months, compared with -38.94% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are MannKind and Nanobiotix S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.